EchoGo Amyloidosis vs Stethee Pro 1
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A (EchoGo Amyloidosis) is a specialized AI-powered screening tool designed for the early detection of cardiac amyloidosis by analyzing echocardiogram video clips. In contrast, Tool B (Stethee Pro 1) is an AI-enabled wireless digital stethoscope system that provides real-time cardiac and respiratory vital sign analysis and sound amplification for broader diagnostic and telemedicine applications. While both leverage AI in cardiology, Tool A focuses on a specific disease screening from imaging, whereas Tool B offers a versatile auscultation and vital sign monitoring solution.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
EchoGou00ae Amyloidosis is an AI-powered screening tool designed to aid in the early detection of cardiac amyloidosis by analyzing echocardiogram video clips. Stethee Pro 1 is an AI-enabled wireless digital stethoscope system that provides real-time cardiac and respiratory vital sign analysis and advanced auscultation for enhanced diagnostics and telemedicine.
EchoGou00ae Amyloidosis is designed for seamless integration with existing clinical workflows and IT infrastructure, including PACS, DICOM, and HL7. Stethee Pro 1 offers secure data capture, analysis, recording, playback, and sharing capabilities via its mobile app and HIPAA-compliant Central Web Portal, with the ability to import data into electronic medical records.
For EchoGou00ae Amyloidosis, inpatient analysis is Medicare-covered with NTAP Code ICD-10 XXE2X19 ($1,000 per analysis), and outpatient analysis is covered by Medicare and select commercial insurers with HCPCS Code C9786 ($285 per analysis). For Stethee Pro 1, the device costs $499, with a subscription required for the Stethee Central web portal for advanced AI-driven analytics; specific reimbursement codes are not provided in the description.
EchoGou00ae Amyloidosis analyzes echocardiogram video clips, focusing on echocardiographic markers like ventricular volume, cardiac function, and myocardial movement, to provide a diagnostic output of 'suggestive' or 'not suggestive' of cardiac amyloidosis. Stethee Pro 1 captures cardiac and respiratory vital signs in 20 seconds, measuring systole, diastole, heart cycle durations, and respiration rate, and provides real-time visualization of heart and lung sounds.
EchoGou00ae Amyloidosis boasts high diagnostic accuracy for cardiac amyloidosis, with 85% sensitivity and 93% specificity, and consistent performance across CA subtypes. Stethee Pro 1 captures cardiac and respiratory vital signs in 20 seconds and offers sophisticated sound amplification (up to 96x) and five proprietary digital filters; its respiration rate detection algorithm showed 99.9% correlation with capnography during clinical validation.
EchoGou00ae Amyloidosis is primarily designed for Cardiology. Stethee Pro 1 is designed for use across Cardiology, Emergency Medicine, and Pulmonology.